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Background The evaluation of neuromuscular diseases includes detailed clinical 
assessment, blood testing, electrodiagnostic studies (EDS), biopsy, and genetic tests. 
EDS alone cannot provide a specific diagnosis. Further testing in the form of genetic 
tests or muscle biopsy (MB) is required.
Objective The objective of the study is to evaluate the yield of MB in patients with 
findings of myopathy on electrodiagnostic testing and assess the factors affecting an 
abnormal biopsy outcome.
Methods Electromyography (EMG)/nerve conduction studies (NCS) performed for 
suspected myopathy over 5 years from 2011 to 2016, at the neurophysiology depart-
ment of a tertiary care center in Pakistan, were reviewed. Based on inclusion criteria, 
records of 58 patients were retrospectively reviewed.
Results After an EMG/NCS diagnosis of myopathy, the frequency of MB testing was 
only 10.1%. The median age of patients was 26.5 years. The clinically suspected diag-
nosis was categorized into hereditary myopathy (n = 15, 25.9%) and acquired myopa-
thy (n = 18, 31%). The positive predictive value of EMG is 77.2%. Twenty-eight (48.2%) 
patients had abnormal MB whereas 20 (34.4%) revealed normal findings. Factors sig-
nificantly influencing an abnormal outcome of biopsy included moderate-to-severe 
elevation of creatine kinase (>2,000 U/L), presence of denervation changes, and severe 
myopathy on EMG.
Conclusion Even though the overall yield of MB testing may not be very high in our 
setting due to the unavailability of special techniques and expertise, certain factors 
can help to improve the diagnostic yield. Clinicians should encourage MB testing, 
especially in cases with strong clinical, laboratory and electrodiagnostic suspicion, and 
absence of genetic testing for suspected myopathy.
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Introduction
Accurate diagnosis of neuromuscular disorders (NMDs) is 
based on a detailed clinical assessment, laboratory and elec-
trodiagnostic testing, histological examination of tissue, and 
genetic tests.1-3 Nerve conduction studies (NCS) and electro-
myography (EMG) are valuable in localizing and assessing 
the severity of NMDs, identifying the distribution of involved 
muscles, and the appropriate muscle to biopsy, and may be 
useful for assessing disease progression. While NCS/EMG can 
suggest a myopathic process, it is seldom useful to provide 
a specific diagnosis, may be technically difficult, especially 
in children and may be subject to operator bias. Therefore, 
further testing in the form of muscle biopsy (MB) or genetic 
testing is required.4,5
MB testing is dependent on proper sampling technique/
handling, muscle selection, expertise of the pathologist, 
availability of numerous stains, and electron microscopic 
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evaluation.6,7 In Pakistan, we face limitations in all of these 
steps. As a result, clinicians have a tendency to rely on clinical 
judgment and avoid an MB to spare patient time, pain, and 
money.
With these limitations, data on the diagnostic yield of 
MB in myopathic disorders are lacking from Pakistan. We 
planned this study to determine the yield of MB in clinically, 
and EMG diagnosed cases of myopathy.
Methods
After approval from Institutional Ethics Review Commit-
tee, 1,290 electrodiagnostic studies (EDS) performed for 
suspected myopathy over 5 years from 2011 to 2016, at the 
neurophysiology department of a large private tertiary care 
university hospital of Pakistan, were reviewed. Of these, 570 
studies showed evidence of myopathy which was based on 
short-mean duration and short amplitude of motor units in 
two or more muscles. Only 58 of these underwent MB testing 
in the same hospital and were included in the study. Medical 
records of these selected cases were retrospectively reviewed 
for demographic, clinical, laboratory, and histopathological 
data.
Clinical data included the suspected diagnosis which was 
categorized into hereditary or acquired myopathy, rate of 
progression of myopathy, and the predominant distribution 
of weakness.
Electrodiagnostic variables included the presence of spon-
taneous activity (positive sharp waves and fibrillation poten-
tials) and the severity of myopathy on needle examination. 
The latter was categorized into mild-to-moderate and severe 
myopathy based on the electromyographer’s assessment. 
Motor units of short duration and amplitude intermixed with 
normal looking motor units were categorized into mild–
moderate category, whereas severe category included only 
myopathic units without any evidence of intermixed normal 
units.
MB data were classified into three main groups, negative 
for myopathy (normal), positive (inflammatory or dystro-
phic), and inconclusive.
Data were compiled and analyzed using IBM SPSS Statis-
tics for Windows Version 19.0 (IBM Corp., Armonk, NY). The 
histopathological diagnosis of muscle biopsies was compared 
with the clinically suspected diagnosis, EMG, and serological 
findings using the Chi-square test.
Results
Of the 570 patients that had a positive EMG for  myopathy 
during the 5 years’ study, only 58 underwent MB test-
ing (10.1%). Patients of all age groups were enrolled in 
the study with a median age of 26.5 years (interquartile 
range = 14–42.2).
Fifteen cases were clinically suspected of having a heredi-
tary myopathy, while 18 were suspected to have an acquired 
myopathy, which included inflammatory myopathy in 17 and 
critical illness myopathy in one patient. Muscle enzymes, 
that is, creatine kinase (CK) and aldolase levels were checked 
in 48 and 21 patients, respectively. About 37.5% had mod-
erate-to-severe elevation of CK (>2,000 U/L). On NCS/EMG, 
severe myopathy was noted in 29 (50%) of cases, and dener-
vation changes suggestive of a necrotizing myopathy were 
seen in 35 (60.3%) patients. One patient showed myotonic 
discharges on EMG with mild-to-moderate severity of myop-
athy electrically. Histopathological analysis of MB turned out 
to be normal in this patient (►Table 1).
Out of 58 patients with myopathic findings on electrodiag-
nostic testing who had MB, 28 (48.2%) had an abnormal biop-
sy result. Sixteen (57.14%) of the abnormal muscle biopsies 
showed inflammatory pathology, 11 (39.2%) had dystrophic 
biopsies of which 3 were dystrophic other than dystrophi-
nopathy and 1 patient showed evidence of steroid-induced 
myopathy (►Fig. 1).
Certain findings on electrodiagnostic tests may have an 
influence on the outcome of MB (►Table  2). Out of the 22 
patients with severe myopathy on EMG, 17 (77.3%) revealed 
an abnormal MB, whereas of those with a mild to moderate 
myogenic needle examination, 15 (57.7%) showed normal 
muscle histopathology. This difference was statistically sig-
nificant (p = 0.02). In addition, the presence of fibrillation 
potentials and positive sharp waves correlated with a posi-
tive MB in 20 (71.4%) cases (p = 0.04). Similarly, the degree of 
elevation of CK correlated significantly with the biopsy result 
as moderate-to-severe elevation of CK was noted in 75% (12) 
of abnormal biopsies (p = 0.02).
Of the 15 patients suspected of a hereditary myopa-
thy, 6 (40%) had dystrophic muscle biopsies. On the other 
hand, 12 out of 18 patients (66.7%) with an acquired myop-
athy yielded a biopsy outcome correlating with the clinical 
 suspicion. A significant number of muscle biopsies revealed 
normal histopathology when the clinical diagnosis was not 
specified, that is, two out of four (50%) or not available (11 
out of 20, 55%). Overall, the correlation of clinically suspected 
diagnosis with the biopsy result did show statistical signifi-
cance (p = 0.002; ►Table 3).
The severity of myopathy on needle examination, the 
presence of denervation changes, and the severity of CK 
elevation, although predictive of an overall positive biopsy 
result, were not very useful in terms of predicting a specific 
histopathological diagnosis and were found in both dystro-
phic and inflammatory muscle biopsies (p = 0.05, 0.07, and 
0.14, respectively; ►Table 3).
Discussion
Genetic testing and/or histopathological analysis of mus-
cles are considered to be definitive tests for the diagnosis of 
myopathic disorders with clinical, serological, and electrodi-
agnostic data providing supporting evidence. Given the lim-
ited availability of genetic testing in Pakistan, much of the 
reliance is on clinical and electrodiagnostic evaluations. MB 
testing although available in certain tertiary care centers is 
poorly relied on by clinicians due to the lack of expertise and 
special techniques. This is evident from the finding that out 
of a total of 570 EMG studies which showed myopathic pro-
cess, only 10.1% underwent MB. Even though we were not 
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 Table 1  Characteristics of the study population
Characteristics n (%)
Age (y)
 Mean 30.6 ± 1.96
 Median (IQR) 26.5.(14–44.2)
Gender
 Male 33 (56.9)
 Female 25 (43.1)
Rate of progression
 Rapid 5 (8.6)
 Moderate 21 (36.2)
 Slow 22 (37.9)
 Unknown 10 (17.2)
Distribution of weakness
 Predominant proximal 41 (70.6)
 Predominant distal 9 (15.5)
 Not available 8 (13.8)
EMG denervation 35 (60.3)
EMG severity
 Mild 11 (19)
 Moderate 18 (31)
 Severe 29 (50)
EMG distribution
 Generalized 27 (46.6)
 Proximal 30 (51.7)
 Distal 1 (1.7)
Serum CKa
 Mean 2,063.08 ± 3,050.1
 Median (IQR) 700.5.(141–2,502.2)
 Normal (<200) 14 (24.1)
 Mild (201–2,000) 16 (27.6)
 Moderate-to-severe 
(>2,000)
18 (31.0)
Serum aldolaseb
 Mean 19.9 ± 22.9
 Median (IQR) 10.(5.1–28.7)
ESRc
 Mean 29.8 ± 30.5
 Median (IQR) 21.(5–47)
Clinical diagnosis
 Hereditary myopathy 15 (25.9)
 Acquired myopathy 18 (31)
 Not specified 5 (8.6)
 Not available 20 (34.5)
(continued)
 Table 1 (continued)
Characteristics n (%)
Biopsy site
 Deltoid 21 (26.2)
 Biceps brachii 18 (31)
 Quadriceps femoris 15 (25.9)
 Gastrocnemius 1 (1.7)
Abbreviations: CK, creatine kinase; EMG, electromyography; ESR, 
erythrocyte sedimentation rate; IQR, interquartile range.
aData available for 48 patients.
bData available for 21 patients.
cData available for 31 patients.
able to account for those patients who may have had an MB 
from a different center, the frequency of MB testing in our 
setting still appears to be very low. This study was performed 
to estimate the overall yield of MB, even with above-men-
tioned limitations, in our setup.
We found that out of a total of 58 muscle biopsies done 
during 2011 to 2016, 28 (48.27%) provided a positive result 
of which 19% were dystrophinopathy, 27.6% were inflamma-
tory, and one showed findings of steroid-induced myopathy. 
The positive diagnostic yield of MB testing reported in differ-
ent studies ranges from 60 to 93%.4,5,8-10
The relatively low rate of positive results on the histo-
pathological analysis in our study can be because of numer-
ous factors. Improper muscle selection for biopsy, inadequate 
amount of the biopsy specimen, lack of use of special stains, 
and electron microscopic examination, limited experience 
of the observer or very advanced stage at the time of biopsy 
testing may contribute to the biopsy outcomes.6,7
Ten cases (17.2%) showed minimal findings for a definitive 
pathological diagnosis. This is almost similar to the finding 
noted by Rabie et al, where 5 out of the 55 patients showed 
nonspecific biopsy findings despite a myopathic EMG.4 
Advanced disease stage, biopsy testing after treatment ini-
tiation, or inadequate sampling technique may contribute to 
these inconclusive results.
In 34.4%, MB turned out to be normal despite the elec-
trodiagnostic evidence of a myopathy. Of these, nine had a 
strong clinical suspicion of myopathy, five had evidence of 
a severe myopathy on EMG, eight had active denervation 
changes on EMG, and eight had elevated muscle enzyme, CK 
(four had CK > 2,000 U/L). These findings raise the possibility 
of a false-negative MB in these cases which can be because of 
the factors mentioned above.
In our study, the positive predictive value of EMG was 
found to be 77.2%. The sensitivity of EMG for diagnosing 
myopathy ranges between 58 and 90% in different studies. 
These figures may vary among different muscles being test-
ed, at different disease stages and in different age groups. It, 
however, tends to be lower (14–75%) in children with age <2 
years.2,4,9,11 This wide variation of sensitivity of EMG among 
different studies probably suggests that evaluation of motor 
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units on needle electrode examination is a subjective assess-
ment of the operator and is subject to interobserver variabil-
ity with both false-positive and false-negative findings. This 
is, therefore, the reason that the diagnostic accuracy of EMG 
for myopathy is reported to be around 60%.2 As EMG testing 
can have false-positive results, therefore, a negative MB in 
cases of mild or even moderate myopathy on EMG testing 
should be interpreted in accordance with other clinical and 
serological evidence.
Conclusion
Based on the findings from this study, it can be suggest-
ed that, even though the overall yield of MB testing may be 
Table 2  Comparison of muscle biopsy findings with clinical, laboratory, and electrodiagnostic dataa
Data Positive biopsy (n = 28)
n (%)
Negative biopsy (n = 20)
n (%)
p-Value
EMG denervation
 Yes 20 (71.4) 8 (28.6)
0.04
 No 8 (40) 12 (60)
Serum CK
 Normal <200 3 (25) 9 (75)
0.02 Mild 201–2000 8 (66.7) 4 (33.3)
 Moderate-to-severe > 001 12 (75) 4 (25)
EMG severity
 Mild to moderate 11 (42.3) 15 (57.7)
0.02
 Severe 17 (77.3) 5 (22.7)
Clinical diagnosis
 Hereditary 7 (63.6) 4 (36.4)
0.06
 Acquired 13 (81.2) 3 (18.8)
 Not specified 2 (50) 2 (50)
 Not available 6 (35.3) 11 (64.7)
Abbreviations: CK, creatine kinase; EMG, electromyography.
aInconclusive biopsies were not included in this analysis.
Fig. 1 Histopathological outcome of muscle biopsy (%).
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Table 3  Comparison of biopsy findings with clinical, laboratory, and electrodiagnostic dataa
Data Inconclusive (n = 10)
n (%)
Inflammatory (n = 16)
n (%)
Dystrophic (n = 11)
n (%)
Normal (n = 20)
n (%)
p-Value
EMG severity
 Mild to moderate 3 (10.3) 6 (20.7) 5 (17.2) 15 (51.7)
0.05
 Severe 7 (25) 10 (35.7) 6 (21.4) 5 (17.9)
EMG denervation
 Yes 7 (20.6) 13 (38.2) 6 (17.6) 8 (23.5)
0.07
 No 3 (13) 3 (13) 5 (21.7) 12 (52.2)
Serum CK
 Normal <200 2 (14.3) 2 (14.3) 1 (7.1) 9 (64.3)
0.14 Mild 201–2000 4 (26.7) 5 (33.3) 2 (13.3) 4 (26.7)
 Moderate to 
severe >2001
2 (11.1) 7 (38.9) 5 (27.8) 4 (22.2)
Clinical diagnosis
 Hereditary 4 (26.7) 1 (6.7) 6 (40) 4 (26.7)
0.002
Acquired 2 (11.2) 12 (66.7) 1 (5.6) 3 (16.7)
 Not specified 1 (25) 1 (25) 0 2 (50)
 Not available 3 (15) 2 (10) 4 (20) 11 (55)
Abbreviations: CK, creatine kinase; EMG, electromyography.
aOne patient with steroid-induced myopathy was excluded from this analysis as it was a separate category. 
lower as compared to other countries, certain factors can 
help to improve the yield. They include moderate-to-severe 
CK elevation, severe myopathy, and presence of fibrillation 
potential/positive sharp waves on EMG. The suspected clin-
ical diagnosis may also have a significant impact. Clinicians 
should encourage MB testing, especially in cases with a 
strong clinical, laboratory, and electrodiagnostic suspicion 
and absence of genetic testing for the suspected myopathy.
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